학술논문

A multitrait genetic study of hemostatic factors and hemorrhagic transformation after stroke treatment
Document Type
Article
Author
Gallego-Fabrega, CristinaTemprano-Sagrera, GerardCárcel-Márquez, JaraMuiño, ElenaCullell, NataliaLledós, MiquelLlucià-Carol, LaiaMartin-Campos, Jesús M.Sobrino, TomásCastillo, JoséMillán, MònicaMuñoz-Narbona, LucíaLópez-Cancio, ElenaRibó, MarcAlvarez-Sabin, JoseJiménez-Conde, JordiRoquer, JaumeTur, SilviaObach, VictorArenillas, Juan F.Segura, TomasSerrano-Heras, GemmaMarti-Fabregas, JoanFreijo-Guerrero, MarimarMoniche, FranciscoCastellanos, Maria del MarMorrison, Alanna C.Smith, Nicholas L.de Vries, Paul S.Fernández-Cadenas, IsraelSabater-Lleal, MariaDehghan, AbbasHeath, Adam S.Morrison, Alanna C.Reiner, Alex P.Johnson, AndrewRichmond, AnnePeters, Annettevan Hylckama Vlieg, AstridMcKnight, BarbaraPsaty, Bruce M.Hayward, CarolineWard-Caviness, CavinO’Donnell, ChristopherChasman, DanielStrachan, David P.Tregouet, David A.Mook-Kanamori, DennisGill, DipenderThibord, FlorianAsselbergs, Folkert W.Leebeek, Frank W.G.Rosendaal, Frits R.Davies, GailHomuth, GeorgTemprano, GerardCampbell, HarryTaylor, Herman A.Bressler, JanHuffman, Jennifer E.Rotter, Jerome I.Yao, JieWilson, James F.Bis, Joshua C.Hahn, Julie M.Desch, Karl C.Wiggins, Kerri L.Díez-Ahijado, LaiaRaffield, Laura M.Bielak, Lawrence F.Yanek, Lisa R.Kleber, Marcus E.Sabater-Lleal, MariaMueller, MartinaKavousi, MaryamMangino, MassimoConomos, Matthew P.Liu, MelissaBrown, Michael R.Jhun, Min-AChen, Ming-Hueide Maat, Moniek P.M.Pankratz, NathanSmith, Nicholas L.Peyser, Patricia A.Elliot, Paulde Vries, Paul S.Wei, PengWild, Philipp S.Morange, Pierre E.van der Harst, PimYang, QiongMarioni, RiccardoLi, RuifangDamrauer, Scott M.Cox, Simon R.Trompet, StellaFelix, Stephan B.Völker, UweTang, WeihongKoenig, WolfgangJukema, J. WouterGuo, Xiuqing
Source
Journal of Thrombosis and Haemostasis; April 2024, Vol. 22 Issue: 4 p936-950, 15p
Subject
Language
ISSN
15387933; 15387836
Abstract
Thrombolytic recombinant tissue plasminogen activator (r-tPA) treatment is the only pharmacologic intervention available in the ischemic stroke acute phase. This treatment is associated with an increased risk of intracerebral hemorrhages, known as hemorrhagic transformations (HTs), which worsen the patient’s prognosis.